Skip to main content
SpringerLink
Log in

Myeloid-Derived Suppressor Cells in Cancer

  • Chapter
  • First Online:
Advances in Tumor Immunology and Immunotherapy

Part of the book series: Current Cancer Research ((CUCR))

  • 2416 Accesses

Abstract

Immune evasion is an emerging hallmark of cancer. Many cancers evade the immune system through the overproduction of a wide array of immunosuppressive cells and cytokines, which not only inhibit the host’s antitumor immune response, but also hinder the clinical efficacy of immune-based therapies. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous collection of immature myeloid cells that play an important role in cancer immune evasion. Their presence has been extensively investigated in preclinical models. MDSCs arise from myeloid progenitor cells that have failed to terminally differentiate into mature granulocytes and macrophages and are recruited from the marrow to the tumor microenvironment through production of various cytokines. One of the major obstacles in developing clinical strategies targeting MDSCs in cancer patients has been their heterogeneity in humans, which thus far has prevented determination of an unambiguous phenotype, shared between mice and humans, that has clinical relevance and correlates with their suppressive function. In this chapter we review the current clinical literature on MDSCs in cancer patients, showing that there appear to be two major subsets of MDSCs which are present under different situations. We also discuss the potential use of MDSC as prognostic and predictive markers in cancer patients. Finally, we examine current strategies designed to modulate MDSCs in cancer patients, which represents an innovative and promising approach to enhance the effectiveness of immune-based therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother. 2012;35(2):107–15.

    Article  PubMed  Google Scholar 

  2. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181(8):5791–802.

    PubMed  CAS  Google Scholar 

  3. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13(7):828–35.

    Article  PubMed  CAS  Google Scholar 

  4. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172(2):989–99.

    PubMed  CAS  Google Scholar 

  5. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111(8):4233–44.

    Article  PubMed  CAS  Google Scholar 

  6. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, Grassi F, Bronte V. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol. 2010;40(1):22–35.

    Article  PubMed  CAS  Google Scholar 

  7. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, Bicciato S, Bronte V. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006;116(10):2777–90.

    Article  PubMed  CAS  Google Scholar 

  8. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, Calabrese F, Basso G, Zanovello P, Cozzi E, Mandruzzato S, Bronte V. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity. 2010;32(6):790–802.

    Article  PubMed  CAS  Google Scholar 

  9. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–74.

    Article  PubMed  CAS  Google Scholar 

  10. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2010;59(10):1593–600.

    Article  PubMed  Google Scholar 

  11. Rodríguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008;222:180–91.

    Article  PubMed  Google Scholar 

  12. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3zeta chain expression by l-arginine. J Biol Chem. 2002;277(24):21123–9.

    Article  PubMed  CAS  Google Scholar 

  13. Rodriguez PC, Quiceno DG, Ochoa AC. l-Arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007;109(4):1568–73.

    Article  PubMed  CAS  Google Scholar 

  14. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008;68(13):5439–49.

    Article  PubMed  CAS  Google Scholar 

  15. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009;182(9):5693–701.

    Article  PubMed  CAS  Google Scholar 

  16. Szuster-Ciesielska A, Hryciuk-Umer E, Stepulak A, Kupisz K, Kandefer-Szerszeń M. Reactive oxygen species production by blood neutrophils of patients with laryngeal carcinoma and antioxidative enzyme activity in their blood. Acta Oncol. 2004;43(3):252–8.

    Article  PubMed  CAS  Google Scholar 

  17. Hamilton MJ, BanĂ¡th JP, Lam V, Lepard NE, Krystal G, Bennewith KL. Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice. Cancer Immunol Immunother. 2012;61(5):643–54.

    Article  PubMed  CAS  Google Scholar 

  18. Mantovani G, MacciĂ² A, Madeddu C, Mura L, Gramignano G, Lusso MR, Massa E, Mocci M, Serpe R. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med (Berl). 2003;81(10):664–73.

    Article  CAS  Google Scholar 

  19. Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R, Jove R, Gabrilovich D. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol. 2004;172(1):464–74.

    PubMed  CAS  Google Scholar 

  20. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001;61(12):4756–60.

    PubMed  CAS  Google Scholar 

  21. Cobbs CS, Whisenhunt TR, Wesemann DR, Harkins LE, Van Meir EG, Samanta M. Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res. 2003;63(24):8670–3.

    PubMed  CAS  Google Scholar 

  22. Bentz BG, Haines GK, Radosevich JA. Increased protein nitrosylation in head and neck squamous cell carcinogenesis. Head Neck. 2000;22(1):64–70.

    Article  PubMed  CAS  Google Scholar 

  23. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res. 2000;6(12):4768–75.

    PubMed  CAS  Google Scholar 

  24. Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Nakao K, Nakamura M, Kakudo K. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res. 2006;12(4):1201–7.

    Article  PubMed  CAS  Google Scholar 

  25. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T, Pagano F, Viola A. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005;201(8):1257–68.

    Article  PubMed  CAS  Google Scholar 

  26. Brito C, Naviliat M, Tiscornia AC, Vuillier F, Gualco G, Dighiero G, Radi R, Cayota AM. Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J Immunol. 1999;162(6):3356–66.

    PubMed  CAS  Google Scholar 

  27. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166(1):678–89.

    PubMed  CAS  Google Scholar 

  28. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O’Neill A, Mier J, Ochoa AC. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005;65(8):3044–8.

    PubMed  CAS  Google Scholar 

  29. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203(12):2691–702.

    Article  PubMed  CAS  Google Scholar 

  30. Filipazzi P, Valenti R, Huber V, et al. (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients and modulation by GM-CSF-based antitumor vaccine. American Society Clinical Oncology Annual Meeting, Chicago; J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 21082

    Google Scholar 

  31. Srivastava MK, Bosch JJ, Thompson JA, Ksander BR, Edelman MJ, Ostrand-Rosenberg S. Lung cancer patients’ CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother. 2008;57(10):1493–504.

    Article  PubMed  CAS  Google Scholar 

  32. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, Garrett-Mayer E, Montero AJ, Bronte V, Mandruzzato S. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. 2011;118(8):2254–65.

    Article  PubMed  CAS  Google Scholar 

  33. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49–59.

    Article  PubMed  CAS  Google Scholar 

  34. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011;60(10):1419–30.

    Article  PubMed  CAS  Google Scholar 

  35. Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, Lee JH, Sondak VK, Riker AI, Deconti RC, Gabrilovich D. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2008;26(19):3235–41.

    Article  PubMed  CAS  Google Scholar 

  36. Wang Y, Chung F, Wang C, et al. (2008) The population alteration of CD11b+/CD14− myeloid-derived suppressor cells in patients with advanced stage, non-small cell lung cancer and the clinical relevance to the responsiveness to epidermal growth factor receptor (EGFR). American Society Clinical Oncology Annual Meeting; Chicago: J Clin Oncol. 2008;26:(Suppl.):Abstract 19082.

    Google Scholar 

  37. Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, Wu YC, Chu Y, Chung FT, Kuo CH, Lee KY, Lin SM, Lin HC, Wang CH, Yu CT, Kuo HP. Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14−/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136(1):35–45.

    Article  PubMed  CAS  Google Scholar 

  38. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, Bronte V, Zanovello P. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol. 2009;182(10):6562–8.

    Article  PubMed  CAS  Google Scholar 

  39. Parrinello N, La Cava P, Tibullo D, et al. (2009) Myeloid-derived suppressor cells in patients with Hodgkin lymphoma. American Society Hematology Annual Meeting Abstracts, New Orleans. Blood. 2009;114:3662.

    Google Scholar 

  40. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010;70(11):4335–45.

    Article  PubMed  CAS  Google Scholar 

  41. Shepard DR, Ireland J, Stephenson AJ, et al. (2010) Effects of sunitinib on immune dysfunction in patients with transitional cell carcinoma (TCC) of the bladder. American Society of Clinical Oncology Genitourinary Cancers Symposium, Orlando, 2010. Abstract-295.

    Google Scholar 

  42. Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, Svane IM. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR−/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol. 2010;72(6):540–7.

    Article  PubMed  CAS  Google Scholar 

  43. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood. 2011;117(3):872–81.

    Article  PubMed  CAS  Google Scholar 

  44. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, KrĂ¼ger C, Manns MP, Greten TF, Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008;135(1):234–43.

    Article  PubMed  CAS  Google Scholar 

  45. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology. 2009;50(3):799–807.

    Article  PubMed  CAS  Google Scholar 

  46. Brandau S, Trellakis S, Bruderek K, Schmaltz D, Steller G, Elian M, Suttmann H, Schenck M, Welling J, Zabel P, Lang S. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol. 2011;89(2):311–7.

    Article  PubMed  CAS  Google Scholar 

  47. Pitini V, Santarpia M, Tomasello C, et al. (2011) Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma. American Society Clinical Oncology Annual Meeting, Chicago, 2011. J Clin Oncol. 2011;29:(Suppl):Abstract e18504.

    Google Scholar 

  48. Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM, Kusmartsev S. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer. 2012;130(5):1109–19.

    Article  PubMed  CAS  Google Scholar 

  49. Fricke I, Mirza N, Dupont J, Lockhart C, Jackson A, Lee JH, Sosman JA, Gabrilovich DI. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res. 2007;13(16):4840–8.

    Article  PubMed  CAS  Google Scholar 

  50. Vuk-Pavlović S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, Dietz AB. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate. 2010;70(4):443–55.

    PubMed  Google Scholar 

  51. Pak AS, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, Young MR. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res. 1995;1(1):95–103.

    PubMed  CAS  Google Scholar 

  52. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69(4):1553–60.

    Article  PubMed  CAS  Google Scholar 

  53. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.

    Article  PubMed  CAS  Google Scholar 

  54. Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, Chang KJ, Chuang EY. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. PLoS One. 2012;7(9):e45831.

    Article  PubMed  CAS  Google Scholar 

  55. Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Masuzaki H, Katabuchi H, Kawakami Y, Okamoto A, Nogawa T, Matsumura N, Udagawa Y, Saito T, Itamochi H, Takano M, Miyagi E, Sudo T, Ushijima K, Iwase H, Seki H, Terao Y, Enomoto T, Mikami M, Akazawa K, Tsuda H, Moriya T, Tajima A, Inoue I, Tanaka K, J. S. O. C. S. Group. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res. 2012;18(5):1374–85.

    Article  PubMed  CAS  Google Scholar 

  56. Lathers DM, Clark JI, Achille NJ, Young MR. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother. 2004;53(5):422–30.

    Article  PubMed  CAS  Google Scholar 

  57. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006;66(18):9299–307.

    Article  PubMed  CAS  Google Scholar 

  58. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, KĂ¼bler H, Yancey D, Dahm P, Vieweg J. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008;14(24):8270–8.

    Article  PubMed  CAS  Google Scholar 

  59. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003;63(15):4441–9.

    PubMed  CAS  Google Scholar 

  60. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, Melani C, Guiducci C, Colombo MP, Iezzi M, Musiani P, Zanovello P, Bronte V. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.". Proc Natl Acad Sci U S A. 2005;102(11):4185–90.

    Article  PubMed  Google Scholar 

  61. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15(6):2148–57.

    Article  PubMed  CAS  Google Scholar 

  62. Wilcox RA, Nevala WK, Thompson MA, et al. (2009) CD14+hla-DR-/lo myeloid-derived suppressor cells express immunosuppressive B7-H family members and are depleted following taxane-based chemotherapy in melanoma. American Society Hematology Annual Meeting Abstracts, New Orleans. Blood. 2009;114:464.

    Google Scholar 

  63. Gabitass RF et al. (2011) Use of gemcitabine- (Gem) and fluropyrimidine (FP)-based chemotherapy to reduce myeloid-derived suppressor cells (MDSCs) in pancreatic (PC) and esophagogastric cancer (EGC). American Society of Clinical Oncology Annual Meeting, Chicago. J Clin Oncol. 2011;29(Suppl):Abstract 2588.

    Google Scholar 

  64. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol. 2009;9(7–8):900–9.

    Article  PubMed  CAS  Google Scholar 

  65. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052–61.

    Article  PubMed  CAS  Google Scholar 

  66. Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, Meyer C, Becerra CR, Fishman M, Antonia S, Sporn MB, Liby KT, Rawal B, Lee JH, Gabrilovich DI. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res. 2010;16(6):1812–23.

    Article  PubMed  CAS  Google Scholar 

  67. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer. 2010;10:464.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

    Christos E. Kyriakopoulos

  2. Taussig Cancer Institute Cleveland Clinic, Cleveland, OH, 44195, USA

    Alberto J. Montero & Claudia Marcela Diaz-Montero

Authors
  1. Christos E. Kyriakopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto J. Montero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudia Marcela Diaz-Montero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alberto J. Montero .

Editor information

Editors and Affiliations

  1. Sylvester Comprehensive Cancer Center (SCCC), University of Miami School of Medicine, Miami, Florida, USA

    Joseph D. Rosenblatt

  2. University of Miami Dept. Microbiology & Immunology, Miami, Florida, USA

    Eckhard R. Podack

  3. University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, USA

    Glen N. Barber

  4. Dept. Pediatrics, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA

    Augusto Ochoa

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kyriakopoulos, C.E., Montero, A.J., Diaz-Montero, C.M. (2014). Myeloid-Derived Suppressor Cells in Cancer. In: Rosenblatt, J., Podack, E., Barber, G., Ochoa, A. (eds) Advances in Tumor Immunology and Immunotherapy. Current Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8809-5_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8809-5_1

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8808-8

  • Online ISBN: 978-1-4614-8809-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation